1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10830)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22056)
  2. Department of Medicine (22034)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5183)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22056)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
    Meeting Abstract

    Wolchok, J. D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Schadendorf, D.; Ferrucci, P. F.; Smylie, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Association of geriatric assessment factors with falls in older adults initiating chemotherapy
    Meeting Abstract

    Wildes, T. M.; Tew, W. P.; Maggiore, R. J.; Edwards, B. J. A.; Cohen, H. J.; Smith, D. D.; Mohile, S. G.; Owusu, C.; Klepin, H. D.; Gross, C. P.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Comprehensive characterization of cisplatin-related hearing loss in US and Canadian Testicular Cancer Survivors (TCS)
    Meeting Abstract

    Wheeler, H. E.; Travis, L. B.; Budnick, A.; Feldman, D. R.; Einhorn, L. H.; Hamilton, R. J.; Vaughn, D. J.; Beard, C.; Fung, C.; Johnson, E.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • TP53 mutations emerge in circulating cell-free DNA obtained from patients undergoing treatment with the HDM2 antagonist SAR405838
    Meeting Abstract

    Watters, J. W.; Dickson, M. A.; Schwartz, G. K.; Le Cesne, A.; Bahleda, R.; Wagner, A. J.; Choy, E.; De Jonge, M. J.; Light, M.; Jung, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E. R.; Rini, B. I.; Atkins, M. B.; Alter, R.; Bhatt, R. S.; Beck, J. T.; Mutyaba, M.; Pappas, K. M.; Wilson, D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features
    Meeting Abstract

    Voss, M. H.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Woo, K.; Redzematovic, A.; Wang, P.; Lee, W.; Patil, S.; Molina, A. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E. R.; Rini, B. I.; Atkins, M. B.; Alter, R.; Bhatt, R. S.; Beck, J. T.; Mutyaba, M.; Pappas, K. M.; Wilson, D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC)
    Meeting Abstract

    Voss, M. H.; Coates, A.; Garmey, E. G.; Haas, N. B.; Hutson, T.; Keefe, S. M.; Motzer, R.; Piscitelli, A.; Vogelzang, N. J.; Figlin, R. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Prospective identification of potentially actionable molecular alterations in cancers of unknown primary
    Meeting Abstract

    Varghese, A. M.; Hyman, D. M.; Zehir, A.; Vakiani, E.; Klimstra, D. S.; Ladanyi, M.; Berger, M. F.; Solit, D. B.; Saltz, L.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO)
    Meeting Abstract

    Turner, N. C.; Balmana, J.; Fasching, P. A.; Hurvitz, S. A.; Telli, M. L.; Visco, F.; Wardley, A. M.; Zhang, C.; Lokker, N. A.; Lounsbury, D. L.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save